METHODS FOR TREATING HYPERCHOLESTEROLEMIA
First Claim
Patent Images
1. An antisense compound having the nucleotide sequence selected from the group consisting of:
- SEQ ID NO;
248, SEQ ID NO;
250, SEQ ID NO;
65, SEQ ID NO;
28, SEQ ID NO;
188, SEQ ID NO;
352, SEQ ID NO;
60, SEQ ID NO;
381, SEQ ID NO;
400, SEQ ID NO;
212, SEQ ID NO;
62, SEQ ID NO;
59, SEQ ID NO;
237, SEQ ID NO;
288, SEQ ID NO;
50, SEQ ID NO;
402, SEQ ID NO;
394, SEQ ID NO;
180, SEQ ID NO;
8, and SEQ ID NO;
7.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
-
Citations
72 Claims
-
1. An antisense compound having the nucleotide sequence selected from the group consisting of:
- SEQ ID NO;
248, SEQ ID NO;
250, SEQ ID NO;
65, SEQ ID NO;
28, SEQ ID NO;
188, SEQ ID NO;
352, SEQ ID NO;
60, SEQ ID NO;
381, SEQ ID NO;
400, SEQ ID NO;
212, SEQ ID NO;
62, SEQ ID NO;
59, SEQ ID NO;
237, SEQ ID NO;
288, SEQ ID NO;
50, SEQ ID NO;
402, SEQ ID NO;
394, SEQ ID NO;
180, SEQ ID NO;
8, and SEQ ID NO;
7. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- SEQ ID NO;
-
16. A composition comprising an antisense compound having the nucleotide sequence selected from the group consisting of:
- SEQ ID NO;
248, SEQ ID NO;
250, SEQ ID NO;
65, SEQ ID NO;
28, SEQ ID NO;
188, SEQ ID NO;
352, SEQ ID NO;
60, SEQ ID NO;
381, SEQ ID NO;
400, SEQ ID NO;
212, SEQ ID NO;
62, SEQ ID NO;
59, SEQ ID NO;
237, SEQ ID NO;
288, SEQ ID NO;
50, SEQ ID NO;
402, SEQ ID NO;
394, SEQ ID NO;
180, SEQ ID NO;
8, and SEQ ID NO;
7, and a pharmaceutically acceptable carrier or diluent. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)
- SEQ ID NO;
-
37. A method comprising administering to an animal an antisense compound having the nucleotide sequence selected from the group consisting of:
- SEQ ID NO;
248, SEQ ID NO;
250, SEQ ID NO;
65, SEQ ID NO;
28, SEQ ID NO;
188, SEQ ID NO;
352, SEQ ID NO;
60, SEQ ID NO;
381, SEQ ID NO;
400, SEQ ID NO;
212, SEQ ID NO;
62, SEQ ID NO;
59, SEQ ID NO;
237, SEQ ID NO;
288, SEQ ID NO;
50, SEQ ID NO;
402, SEQ ID NO;
394, SEQ ID NO;
180, SEQ ID NO;
8, and SEQ ID NO;
7. - View Dependent Claims (38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)
- SEQ ID NO;
-
72. A modified antisense oligonucleotide having the nucleotide sequence of SEQ ID NO:
- 248, wherein the modified oligonucleotide comprises;
a gap segment consisting of ten linked deoxynucleosides; a 5′
wing segment consisting of five linked nucleosides; anda 3′
wing segment consisting of five linked nucleosides;wherein the gap segment is positioned between the 5′
wing segment and the 3′
wing segment, wherein each nucleoside of each wing segment comprises a 2′
-O-methoxyethyl sugar;
wherein each internucleoside linkage is a phosphorothioate linkage, and wherein each cytosine nucleoside in the modified antisense oligonucleotide is a 5-methylcytosine.
- 248, wherein the modified oligonucleotide comprises;
Specification